Maksim Mamonkin, PhD
- Immunobiology of chimeric antigen receptor (CAR) T cells,
- Adoptive T cell therapy of cancer and autoimmune diseases,
- Synthetic biology in cell therapies
The main research interest of his laboratory is studying immunobiology of T-cells engineered with chimeric antigen receptors (CARs) and creating new cell therapies for devastating diseases. He investigates molecular mechanisms regulating the activity of CAR T-cells and develop new ideas, from bench all the way to bedside. In particular, he is utilizing protein engineering and CRISPR-mediated genome editing to create therapeutic T-cells that target malignant T-cells (T-ALL, T-cell lymphoma) with minimal damage to normal lymphocytes. He is also exploring new strategies to target pathogenic T-cells in the context of immune rejection and autoimmune diseases. These approaches are currently being translated to the clinic and evaluated in ongoing and upcoming Phase I clinical trials at Baylor College of Medicine.
ASH Scholar Award (Basic/Translational Fellow), Increasing safety of CD5 CAR for the treatment of T cell tumors
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.